MEI Pharma, Inc. (MEIP)
Stock Price Chart
Key Info
| Market Cap | 288.32M |
| Revenue (ttm) | 4.54M |
| Net Income (ttm) | -24.49M |
| Shares Out | 106.00M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 10, 2020 |
| Last Price | $2.72 |
| Previous Close | $2.78 |
| Change ($) | -0.06 |
| Change (%) | -2.16% |
| Day's Open | 2.81 |
| Day's Range | 2.68 - 2.81 |
| Day's Volume | 575,499 |
| 52-Week Range | 0.72 - 4.46 |
More Stats
| Market Cap | 288.32M |
| Enterprise Value | 195.52M |
| Earnings Date (est) | Sep 2, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 106.00M |
| Float | 78.23M |
| EPS (basic) | -37035.8 |
| EPS (diluted) | -0.47 |
| FCF / Share | -0.41 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 6.41M |
| Short Ratio | 2.36 |
| Short % of Float | 5.64% |
| Beta | 1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 63.52 |
| PB Ratio | 3.87 |
| Revenue | 4.54M |
| Operating Income | -48.92M |
| Net Income | -24.49M |
| Free Cash Flow | -43.71M |
| Net Cash | 92.80M |
| Net Cash / Share | 0.88 |
| Gross Margin | 14.36% |
| Operating Margin | -1,077.84% |
| Profit Margin | -539.50% |
| FCF Margin | -963.05% |
| ROA | -33.50% |
| ROE | -43.58% |
| ROIC | 358.50% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.92 | 1.62 | 23.25 | - | - | - | - | - | - | - |
| Revenue Growth | 203.02% | -93.02% | - | - | - | - | - | - | - | - |
| Gross Profit | 0.65 | -1.76 | 18.25 | - | - | - | - | - | - | - |
| Operating Income | -46.25 | -28.59 | 2.38 | -21.00 | -32.77 | -27.23 | -11.22 | -8.39 | -6.45 | -7.98 |
| Net Income | -16.82 | -40.07 | 2.67 | -20.86 | -32.69 | -27.15 | -11.19 | -7.52 | -6.78 | -7.90 |
| Shares Outstanding | 71.14 | 41.43 | 36.81 | 34.40 | 28.20 | 20.06 | 10.16 | 2.25 | 1.27 | 1.22 |
| Earnings Per Share | -54,613.00 | -40,068.00 | 2,670.00 | -0.61 | -1.16 | -1.35 | -1.10 | -3.35 | -5.34 | -6.42 |
| Operating Cash Flow | -29.42 | -21.04 | 3.49 | -17.86 | -28.07 | -19.45 | -10.04 | -7.08 | -6.50 | -10.03 |
| Capital Expenditures | -0.22 | - | -0.05 | - | -0.02 | -0.05 | -0.04 | - | -0.05 | - |
| Free Cash Flow | -29.64 | -21.04 | 3.44 | -17.86 | -28.08 | -19.50 | -10.08 | -7.08 | -6.55 | -10.04 |
| Cash & Equivalents | 74.49 | 103 | 53.57 | 45.92 | 63.78 | 48.79 | 35.57 | 6.20 | 3.86 | 9.03 |
| Net Cash / Debt | 74.49 | 103 | 53.57 | 45.92 | 63.78 | 48.79 | 35.57 | 6.20 | 3.86 | 9.03 |
| Assets | 82.66 | 105 | 55.70 | 47.16 | 64.75 | 49.81 | 36.55 | 6.37 | 4.17 | 9.14 |
| Liabilities | 34.73 | 54.20 | 4.87 | 5.51 | 4.96 | 4.62 | 1.68 | 1.77 | 2.37 | 1.76 |
| Book Value | 47.93 | 50.46 | 50.84 | 41.65 | 59.79 | 45.19 | 34.87 | 4.60 | 1.79 | 7.38 |
Company Profile
Company Details
| Full Name | MEI Pharma, Inc. |
| Country | United States |
| Employees | 40 |
| CEO | Daniel P. Gold |
Stock Information
| Ticker Symbol | MEIP |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: MEIP |
| IPO Date | December 19, 2003 |
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory follicular lymphoma and B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor for B-cell malignancies and AML. In addition, the company engages in the development of ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex for the treatment of HER2-negative breast cancer. MEI Pharma, Inc. has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and a license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor, as well as related compounds. The company also has a license agreement with CyDex Pharmaceuticals, Inc. for Captisol to use with ME-344, which are isoflavone-based drug compounds; a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies; and a license agreement with Kyowa Kirin Co., Ltd. for ME-401. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.